Evidence map›Paper›PMID 36551559›Full record

ArticleCancers2022

Cytology Smears: An Enhanced Alternative Method for Colorectal Cancer pN Stage-A Multicentre Study.

Sherley Diaz-Mercedes, Ivan Archilla, Sara Lahoz, Maria Teresa Rodrigo-Calvo, Sandra Lopez-Prades, Jordi Tarragona, Stefania Landolfi, Angel Concha, Isidro Machado, Joan Maurel and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Sherley Diaz-MercedesDepartment of Pathology, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-8164-8639
Ivan ArchillaDepartment of Pathology, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-2142-0608
Sara LahozInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Maria Teresa Rodrigo-CalvoDepartment of Pathology, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.
Sandra Lopez-PradesDepartment of Pathology, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.
Jordi TarragonaPathology Department, Hospital Arnau de Vilanova, 25198 Lleida, Spain.ORCID 0000-0002-1459-4087
Stefania LandolfiPathology Department, Vall de Hebron University Hospital, 08035 Barcelona, Spain.
Angel ConchaDepartment of Pathology, University Hospital A Coruña, 15006 A Coruña, Spain.
Isidro MachadoPathology Department, Instituto Valenciano de Oncologia, 46009 Valencia, Spain.
Joan MaurelInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-9413-5592
Nuria ChicOncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Antoni CastellsInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Francesc BalaguerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-0206-0539
Jordi CampsInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Miriam CuatrecasasDepartment of Pathology, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-3063-0110
Hospital Clínic de Barcelona · ESFundación Instituto Valenciano de Oncología · ESHospital Arnau de Vilanova · ESUniversidade da Coruña · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca GRPRE 2017SGR21, GRC 2017SGR653, 2017SGR1282; 2017SGR1035COST Action CA17118Instituto de Salud Carlos III FI18/00221Instituto de Salud Carlos III PI17/01304; PI20/00863
6 · The paper itself

Abstract

Stage II colorectal cancer (CRC) recurrence remains a clinical problem. Some of these patients are true stage III CRC with a pN0 pathology stage. This large prospective multicentre cohort study aimed at evaluating the diagnostic ability of lymph node (LN) cytology smears to perform the pN stage and compare it with the conventional haematoxylin and eosin (H&E) pathology pN stage. Additionally, we used the One-Step Nucleic Acid Amplification (OSNA), a high-sensitive molecular method of LN staging. A total of 3936 fresh LNs from 217 CRC surgical specimens were examined by three methods, H&E, LN cytology smears, and OSNA. H&E detected 29% of patients with positive LNs, cytology smears 35%, and OSNA 33.2% (p < 0.0001). H&E and cytology concordantly classified 92.2% of tumours, and 88.5% between OSNA and H&E. Cytology had 96.8% sensitivity and 90.3% specificity to discriminate positive/negative patients compared to H&E (p = 0.004), and 87.3% sensitivity and 89% specificity when compared to OSNA (p = 0.56). Patients with positive LNs detected by any of the three methods had significantly worse disease-free and overall survival. We conclude that pN stage accuracy for detecting positive LNs is superior with LN cytological smears than with conventional H&E, which would enable a better pN stage and management of early-stage CRC patients.

Indexed as

colorectal cancercytologydiagnosislymph nodeOSNAstaging

Identifiers

PMID36551559
PMCPMC9775901
OpenAlexW4312126543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.